Stock-Based Compensation (Tables)

3 Months Ended

May 04, 2024

Share-Based Payment Arrangement [Abstract]

Schedule of Compensation Costs

The stock-based compensation costs that have been charged against income were as follows (in thousands):

	13-Weeks Ended
	May 4, 2024		April 29, 2023
Stock-based compensation expense by type:
Stock options	$	—	$	220
Restricted stock units	2,320		1,653
Employee stock purchases	134		106
Director deferred compensation	27		26
Total stock-based compensation expense	2,481		2,005
Income tax benefit recognized	572		454
Stock-based compensation expense, net of income tax	$	1,909	$	1,551

Schedule of Equity Awards Granted

We granted the following equity awards:

	13-Weeks Ended
	May 4, 2024	April 29, 2023
Stock options	—	8,188
Restricted stock unit awards	59,841	78,515
Performance-based restricted stock unit awards	33,211	39,567
Deferred stock units	359	450

Schedule of Stock Options Granted, Exercise Price Per Share and Weighted-average Grant Date Fair Value

Details of stock options granted, exercise price per share and the weighted-average grant date fair value were as follows:

	13-Weeks Ended
	May 4, 2024		April 29, 2023
Total stock options granted	—		8,188
Exercise price	$	—	$	58.38
Fair value of stock options	$	—	$	26.87

Schedule of Shares Purchased

The number of shares purchased, the average price per share and the weighted-average grant date fair value of shares purchased through our employee stock purchase plan were as follows:

	13-Weeks Ended
	May 4, 2024		April 29, 2023
Shares purchased	7,170		7,026
Average price per share	$	61.22	$	50.13
Weighted-average fair value at grant date	$	18.90	$	17.60